These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34221460)

  • 1. Pharmacovigilance: Basic concepts and an overview of the system in Oman.
    Jose J; Al Rubaie MH; Al Ramimmy H; Varughese SS
    Sultan Qaboos Univ Med J; 2021 May; 21(2):e161-e163. PubMed ID: 34221460
    [No Abstract]   [Full Text] [Related]  

  • 2. Strengths and Weaknesses of the Pharmacovigilance Systems in Three Arab Countries: A Mixed-Methods Study Using the WHO Pharmacovigilance Indicators.
    Garashi H; Steinke D; Schafheutle E
    Int J Environ Res Public Health; 2022 Feb; 19(5):. PubMed ID: 35270208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland's ambiguity-conflict model.
    Garashi HY; Steinke DT; Schafheutle EI
    Global Health; 2021 Aug; 17(1):97. PubMed ID: 34461946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance in the Middle East: a survey of 13 arabic-speaking countries.
    Wilbur K
    Drug Saf; 2013 Jan; 36(1):25-30. PubMed ID: 23315293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of this issue: pharmacovigilance, what is new?
    Martin LG; Hanssens Y; Paudyal V
    Int J Clin Pharm; 2018 Aug; 40(4):737-739. PubMed ID: 30132234
    [No Abstract]   [Full Text] [Related]  

  • 8. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.
    de Vries ST; Denig P; Ekhart C; Burgers JS; Kleefstra N; Mol PGM; van Puijenbroek EP
    Br J Clin Pharmacol; 2019 Jul; 85(7):1507-1515. PubMed ID: 30941789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].
    Aguirre C; García M
    Med Clin (Barc); 2016 Nov; 147(10):461-464. PubMed ID: 27450163
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.
    Danton AC; Montastruc F; Sommet A; Durrieu G; Bagheri H; Bondon-Guitton E; Lapeyre-Mestre M; Montastruc JL
    Eur J Clin Pharmacol; 2013 Apr; 69(4):885-8. PubMed ID: 22996074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
    Awada Z; Zgheib NK
    Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions reporting culture in Pharmacovigilance Programme of India.
    Kalaiselvan V; Prasad T; Bisht A; Singh S; Singh GN
    Indian J Med Res; 2014 Oct; 140(4):563-4. PubMed ID: 25488454
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of pitolisant: a study in the WHO international pharmacovigilance database.
    Montastruc JL
    Eur J Clin Pharmacol; 2023 Apr; 79(4):569-570. PubMed ID: 36892631
    [No Abstract]   [Full Text] [Related]  

  • 16. Uses of pharmacovigilance databases: An overview.
    Bihan K; Lebrun-Vignes B; Funck-Brentano C; Salem JE
    Therapie; 2020; 75(6):591-598. PubMed ID: 32169289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Notification of adverse drug events in Brazil: profile of professionals who notify the Brazilian pharmacovigilance system].
    Melo JRR; Duarte EC; Arrais PSD
    Cad Saude Publica; 2021; 37(11):e00237221. PubMed ID: 34816955
    [No Abstract]   [Full Text] [Related]  

  • 18. An historical overview over Pharmacovigilance.
    Fornasier G; Francescon S; Leone R; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):744-747. PubMed ID: 29948743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
    Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
    Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.